Robinson Smith Wealth Advisors LLC Boosts Stake in Amgen Inc. (NASDAQ:AMGN)

Robinson Smith Wealth Advisors LLC lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 8.8% in the 4th quarter, Holdings Channel reports. The firm owned 805 shares of the medical research company’s stock after acquiring an additional 65 shares during the period. Robinson Smith Wealth Advisors LLC’s holdings in Amgen were worth $210,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. Signature Wealth Management Group grew its holdings in shares of Amgen by 126.2% in the fourth quarter. Signature Wealth Management Group now owns 1,796 shares of the medical research company’s stock worth $468,000 after acquiring an additional 1,002 shares during the period. First National Advisers LLC grew its holdings in shares of Amgen by 1.6% in the fourth quarter. First National Advisers LLC now owns 18,333 shares of the medical research company’s stock worth $4,778,000 after acquiring an additional 288 shares during the period. GWN Securities Inc. bought a new stake in shares of Amgen in the fourth quarter worth $659,000. Gallacher Capital Management LLC grew its holdings in shares of Amgen by 12.4% in the fourth quarter. Gallacher Capital Management LLC now owns 1,115 shares of the medical research company’s stock worth $291,000 after acquiring an additional 123 shares during the period. Finally, Patten & Patten Inc. TN grew its holdings in shares of Amgen by 2.2% in the fourth quarter. Patten & Patten Inc. TN now owns 3,012 shares of the medical research company’s stock worth $785,000 after acquiring an additional 65 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

AMGN has been the subject of several research analyst reports. Bank of America lifted their price objective on Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a report on Wednesday, March 5th. UBS Group reissued a “hold” rating on shares of Amgen in a report on Wednesday, February 12th. StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Johnson Rice set a $294.00 price target on Amgen in a report on Wednesday, March 5th. Finally, Redburn Partners cut their price target on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $314.04.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP David M. Reese sold 25,225 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the transaction, the executive vice president now directly owns 36,922 shares in the company, valued at approximately $11,240,533.68. This represents a 40.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock worth $20,644,335 over the last ninety days. Company insiders own 0.69% of the company’s stock.

Amgen Trading Up 0.3 %

Shares of AMGN stock opened at $313.71 on Friday. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The stock’s 50 day simple moving average is $291.82 and its two-hundred day simple moving average is $299.33. The company has a market cap of $168.53 billion, a PE ratio of 41.55, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.03%. Amgen’s dividend payout ratio (DPR) is presently 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.